576 related articles for article (PubMed ID: 25660156)
21. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
[TBL] [Abstract][Full Text] [Related]
23. TRIBE-2: a phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group.
Cremolini C; Marmorino F; Loupakis F; Masi G; Antoniotti C; Salvatore L; Schirripa M; Boni L; Zagonel V; Lonardi S; Aprile G; Tamburini E; Ricci V; Ronzoni M; Pietrantonio F; Valsuani C; Tomasello G; Passardi A; Allegrini G; Di Donato S; Santini D; Falcone A;
BMC Cancer; 2017 Jun; 17(1):408. PubMed ID: 28599628
[TBL] [Abstract][Full Text] [Related]
24. FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study.
Kochi M; Akiyama Y; Aoki T; Hagiwara K; Takahashi T; Hironaka K; Teranishi F; Osuka F; Takeuchi M; Fujii M; Nakajima T
Cancer Chemother Pharmacol; 2013 Nov; 72(5):1097-102. PubMed ID: 24057041
[TBL] [Abstract][Full Text] [Related]
25. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.
Heinemann V; von Weikersthal LF; Decker T; Kiani A; Vehling-Kaiser U; Al-Batran SE; Heintges T; Lerchenmüller C; Kahl C; Seipelt G; Kullmann F; Stauch M; Scheithauer W; Hielscher J; Scholz M; Müller S; Link H; Niederle N; Rost A; Höffkes HG; Moehler M; Lindig RU; Modest DP; Rossius L; Kirchner T; Jung A; Stintzing S
Lancet Oncol; 2014 Sep; 15(10):1065-75. PubMed ID: 25088940
[TBL] [Abstract][Full Text] [Related]
26. Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Bendell JC; Tournigand C; Swieboda-Sadlej A; Barone C; Wainberg ZA; Kim JG; Pericay C; Pastorelli D; Tarazi J; Rosbrook B; Bloom J; Ricart AD; Kim S; Sobrero AF
Clin Colorectal Cancer; 2013 Dec; 12(4):239-47. PubMed ID: 24188685
[TBL] [Abstract][Full Text] [Related]
27. Liver resection following FOLFOXIRI plus bevacizumab: a detailed pathological review.
Walter H; Thomas AL
Br J Cancer; 2013 Jun; 108(12):2417-8. PubMed ID: 23801031
[No Abstract] [Full Text] [Related]
28. Bevacizumab with chemotherapy in patients with KRAS wild-type metastatic colorectal cancer: Czech registry data.
Kubáčková K; Bortlíček Z; Pikus T; Linke Z; Pokorná P; Vyzula R; Prausová J
Future Oncol; 2015; 11(2):225-32. PubMed ID: 25591837
[TBL] [Abstract][Full Text] [Related]
29. Cetuximab or bevacizumab in metastatic colorectal cancer?
Sclafani F; Cunningham D
Lancet Oncol; 2014 Sep; 15(10):1040-1. PubMed ID: 25088941
[No Abstract] [Full Text] [Related]
30. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
31. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
32. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Matsuoka A; Maeda O; Ando Y
N Engl J Med; 2015 Jan; 372(3):291. PubMed ID: 25587962
[No Abstract] [Full Text] [Related]
33. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Haines IE
N Engl J Med; 2015 Jan; 372(3):290-1. PubMed ID: 25587961
[No Abstract] [Full Text] [Related]
34. FOLFOXIRI and bevacizumab for metastatic colorectal cancer.
Cremolini C; Loupakis F; Falcone A
N Engl J Med; 2015 Jan; 372(3):291-2. PubMed ID: 25587960
[No Abstract] [Full Text] [Related]
35. Chemotherapy of metastatic colorectal cancer: fluorouracil plus folinic acid and irinotecan or oxaliplatin.
Prescrire Int; 2005 Dec; 14(80):230-3. PubMed ID: 16400749
[TBL] [Abstract][Full Text] [Related]
36. The use of high dose d,l-leucovorin in first-line bevacizumab+mFOLFIRI treatment of patients with metastatic colorectal cancer may enhance the antiangiogenic effect of bevacizumab.
Budai B; Nagy T; Láng I; Hitre E
Angiogenesis; 2013 Jan; 16(1):113-21. PubMed ID: 22956187
[TBL] [Abstract][Full Text] [Related]
37. FOLFIRI combined with bevacizumab as first-line treatment for metastatic colorectal cancer patients with hyperbilirubinemia after UGT1A1 genotyping.
Yeh YS; Huang ML; Chang SF; Chen CF; Hu HM; Wang JY
Med Princ Pract; 2014; 23(5):478-81. PubMed ID: 24642571
[TBL] [Abstract][Full Text] [Related]
38. Clinical outcome of elderly patients with metastatic colorectal cancer treated with FOLFOXIRI versus FOLFIRI: Subgroup analysis of a randomized phase III trial from the Hellenic Oncology Research Group (HORG).
Vamvakas L; Athanasiadis A; Karampeazis A; Kakolyris S; Polyzos A; Kouroussis Ch; Ziras N; Kalbakis K; Georgoulias V; Souglakos J
Crit Rev Oncol Hematol; 2010 Oct; 76(1):61-70. PubMed ID: 19729318
[TBL] [Abstract][Full Text] [Related]
39. Safety and efficacy of modified FOLFOX6 plus high-dose bevacizumab in second-line or later treatment of patients with metastatic colorectal cancer.
Takii Y; Maruyama S
Chemotherapy; 2013; 59(2):79-84. PubMed ID: 23881273
[TBL] [Abstract][Full Text] [Related]
40. Short time infusion of bevacizumab in combination with 5FU-based chemotherapy as first-line therapy in a non-selective patient group with metastatic colorectal cancer.
Dohn LH; Jensen BV; Larsen FO
Acta Oncol; 2010 Apr; 49(3):395-6. PubMed ID: 20001495
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
